NextCure  Inc (NXTC)

Currency in USD
4.990
-0.240(-4.59%)
Real-time Data·
NXTC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NXTC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.9105.095
52 wk Range
2.68820.760
Key Statistics
Prev. Close
5.2
Open
5.002
Day's Range
4.91-5.095
52 wk Range
2.688-20.76
Volume
8.56K
Average Volume (3m)
116.85K
1-Year Change
-71.3%
Book Value / Share
23.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NXTC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.500
Upside
+411.02%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

NextCure  Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

NextCure  Inc Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Compare NXTC to Peers and Sector

Metrics to compare
NXTC
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.5x−0.5x
PEG Ratio
−0.01−0.010.00
Price/Book
0.2x2.6x2.6x
Price / LTM Sales
-161.8x3.3x
Upside (Analyst Target)
390.4%178.1%42.8%
Fair Value Upside
Unlock−1.3%6.5%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 25.500
(+411.02% Upside)

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
-- / -0.425
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NXTC Income Statement

People Also Watch

15.92
SRPT
-4.99%
0.540
WINT
+1.48%
34.40
BMNR
+3.30%
0.92
KLTO
-5.97%
5.44
REPL
-14.00%

FAQ

What Stock Exchange Does NextCure Trade On?

NextCure is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for NextCure?

The stock symbol for NextCure is "NXTC."

What Is the NextCure Market Cap?

As of today, NextCure market cap is 13.35M.

What Is NextCure's Earnings Per Share (TTM)?

The NextCure EPS (TTM) is -21.23.

When Is the Next NextCure Earnings Date?

NextCure will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is NXTC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has NextCure Stock Split?

NextCure has split 1 times.

How Many Employees Does NextCure Have?

NextCure has 43 employees.

What is the current trading status of NextCure (NXTC)?

As of 06 Aug 2025, NextCure (NXTC) is trading at a price of 4.99, with a previous close of 5.20. The stock has fluctuated within a day range of 4.91 to 5.10, while its 52-week range spans from 2.69 to 20.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.